Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Cassiopea gets U.S. FDA approval for acne treatment Winlevi

08/27/2020 | 02:24am EST

Swiss-listed drugmaker Cassiopea said on Thursday it won approval for its first medicine, an acne treatment, from the U.S. Food and Drug Administration, setting the stage for a likely capital increase to support its launch.

Winlevi, a twice-daily topical prescription medicine that targets hormones called androgens, won approval for males and females 12 years and older, Cassiopea said. Winlevi reduced acne in trials. The most frequent local reaction was skin redness, or erythema.

Historically, acne has been treated by drugs called retinoids that help unplug hair follicles, and antibiotics that kill excess skin bacteria.

The drug is expected to be available in the United States in early 2021 and Cassiopea plans to announce the price in the fourth quarter. It did not give sales expectations.

The company was spun off in 2015 by Cosmo Pharmaceuticals into a separate firm listed on the Swiss stock exchange. Cosmo still owns just under half of Cassiopea.

"We are excited to bring our first prescription drug to the market and have built a detailed strategic and tactical launch plan," said Cassiopea Chief Executive Diana Harbort, adding Cosmo would support Cassiopea's plan to raise more capital for the launch, but likely eventually monetize its investment.

The drug is also being studied against hair-loss causing alopecia.

Cassiopea shares are up about 10% this year.

(Reporting by John Miller and Silke Koltrowitz; editing by Thomas Seythal and Shailesh Kuber)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CASSIOPEA S.P.A. -0.65% 45.6 Delayed Quote.9.29%
COSMO PHARMACEUTICALS N.V. -0.24% 83.3 Delayed Quote.8.87%
Latest news "Companies"
07:23aDow's Rise to 30000 Heralds a Broader Stock Rally
DJ
07:22a‘DON'T WASTE OUR ENERGY' : Good Energy calls out over-consumption on Black Friday
PU
07:21aRWE : European Commissions approves German hard coal exit tender
RE
07:21a70 & 75-INCH TV BLACK FRIDAY DEALS 2020 : Samsung, LG, TCL & More 4K Smart TV Sales Rounded Up by Retail Fuse
BU
07:21aBLACK FRIDAY ROOMBA S9 DEALS (2020) : Roomba s9 & s9+ Deals Listed by Retail Egg
BU
07:21aBEST BLACK FRIDAY BASKETBALL HOOP DEALS (2020) : Spalding, Lifetime & More Basketball Goal Sales Researched by Deal Stripe
BU
07:19aEU must accept reality to move fisheries talks forward, says PM
RE
07:18aNETFLIX : What's coming and going in December 2020
AQ
07:17aTESLA : issues two recalls covering 9,500 U.S. vehicles - NHTSA
RE
07:17aGAP, DEERE, HP, DELL : What to Watch When the Market Opens Today
DJ
Latest news "Companies"